Stephen Kaminsky
19Patents
3h-index
23Co-inventors
56Inventor score
Filing activity: Mar 17, 2011 → Jun 5, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9464131B2 | Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody | Chemistry; Metallurgy | 14 | Active |
| US10087239B2 | Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody | Chemistry; Metallurgy | 12 | Active |
| US9682133B2 | Disrupted adenovirus-based vaccine against drugs of abuse | Chemistry; Metallurgy | 8 | Active |
| US12122844B2 | Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies | Chemistry; Metallurgy | 2 | Active |
| US11319362B2 | Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies | Chemistry; Metallurgy | 2 | Active |
| US12024568B2 | Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies | Chemistry; Metallurgy | 1 | Active |
| US11584789B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US10407493B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US12410243B2 | Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies | Chemistry; Metallurgy | 0 | Active |
| US12312396B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US10865234B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US10093947B2 | AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation | Chemistry; Metallurgy | 0 | Active |
| US10239934B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US12031144B2 | Oxidation-resistant AAT gene therapy | Chemistry; Metallurgy | 0 | Active |
| US12018067B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US11845789B2 | Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies | Chemistry; Metallurgy | 0 | Active |
| US10004811B2 | Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction | Human Necessities | 0 | Active |
| US9920111B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US10836811B2 | Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.